Empowered Patient Podcast

Dr. Sandra Silberman, Chief Medical Officer at CNS Pharmaceuticals, has developed new therapies for glioblastoma that can cross the blood-brain barrier to reach brain tumors. Their lead drug candidates have been modified to slip into the membranes to inhibit tumor growth and attack the cancer cells. The anthracycline-based and taxane-based drugs are showing efficacy in clinical trials and are not showing the cardiotoxicity associated with anthracyclines.

Sandra explains, "Anthracyclines are characteristically cardiotoxic. And we have just conducted a study of over 160 patients who have received this, and some of them for quite a long period of time. And we have not seen any cardiotoxicity. So we have one of the anthracyclines that is the first to actually cross the blood-brain barrier without any help from other mechanisms, and it also doesn't cause cardiotoxicity. So we have a really open field to be able to further develop this drug. And we know that this drug, based on all of our preclinical studies, is very effective against glioma cells."

"This is to the great credit of the chemists that we've been working with. Can I develop a compound that can not be a substrate for this, so it can't even bind to this efflux transporter and can slip by? But not only that, can it be lipophilic, meaning it can get through all those membranes, and it can be something that leaks into the brain itself. So the two molecules that we have are not substrates for these multidrug-resistant transporters. They're also very highly lipophilic, meaning they're very oily. And so I guess this has two meanings to it, but they're oily and then they slip into the brain and are able to do what they're supposed to be doing, which is the inhibition of tumor growth and killing the tumor cells."

#CNSPharma #Glioblastoma ##BrainCancer #BloodBrainBarrier #NeuroOncology #CancerResearch #DrugDevelopment #BrainTumor

cnspharma.com

Listen to the podcast here

Dr. Sandra Silberman, Chief Medical Officer at CNS Pharmaceuticals, has developed new therapies for glioblastoma that can cross the blood-brain barrier to reach brain tumors. Their lead drug candidates have been modified to slip into the membranes to inhibit tumor growth and attack the cancer cells. The anthracycline-based and taxane-based drugs are showing efficacy in clinical trials and are not showing the cardiotoxicity associated with anthracyclines.

Sandra explains, "Anthracyclines are characteristically cardiotoxic. And we have just conducted a study of over 160 patients who have received this, and some of them for quite a long period of time. And we have not seen any cardiotoxicity. So we have one of the anthracyclines that is the first to actually cross the blood-brain barrier without any help from other mechanisms, and it also doesn't cause cardiotoxicity. So we have a really open field to be able to further develop this drug. And we know that this drug, based on all of our preclinical studies, is very effective against glioma cells."

"This is to the great credit of the chemists that we've been working with. Can I develop a compound that can not be a substrate for this, so it can't even bind to this efflux transporter and can slip by? But not only that, can it be lipophilic, meaning it can get through all those membranes, and it can be something that leaks into the brain itself. So the two molecules that we have are not substrates for these multidrug-resistant transporters. They're also very highly lipophilic, meaning they're very oily. And so I guess this has two meanings to it, but they're oily and then they slip into the brain and are able to do what they're supposed to be doing, which is the inhibition of tumor growth and killing the tumor cells."

#CNSPharma #Glioblastoma ##BrainCancer #BloodBrainBarrier #NeuroOncology #CancerResearch #DrugDevelopment #BrainTumor

cnspharma.com

Download the transcript here

Kevin Caldwell, CEO, President, and Co-Founder of Ossium Health, discusses the opportunities for regenerative stem-cell therapies and the challenges of obtaining bone marrow from donors for bone marrow transplants. Ossium Health is collecting bone marrow from healthy, young donors and utilizing a cryopreservation process that enables long-term storage and on-demand availability of these cells. Ongoing clinical trials using allogeneic bone-marrow-derived cells to treat patients with acute leukemia and myelodysplastic syndrome are showing promising results.

Kevin explains, "Our mission is to improve the health, longevity, and vitality of human beings through bioengineering. We believe that regenerative therapeutics, which involve cell and gene therapies that can permanently and positively improve human biology, will be fundamental to the prevention of disease and the preservation of health as we age. One of the most powerful tools we have in achieving this goal is engineering the immune system. And in particular at Ossium, we develop therapeutics that enable us today in the clinic to treat life-threatening malignancies of the immune system, like leukemia, in patients with dire need. Into the future, the goal is to make it possible to reconstitute, reprogram, and replace a blood and immune system in a manner that can treat patients with chronic diseases and ultimately do so in a preventive manner."

"Traditionally, the major application of bone marrow in the clinic is bone marrow transplants for patients with blood cancers like leukemia. And so the patient's native immune system is ablated or annihilated and replaced with a bone marrow infusion from a healthy donor, related or unrelated. And if that bone, new bone marrow from the donor in grafts in the patient, then it replaces or it constitutes their blood and immune system."

"And so one of the things that we're working on at Ossium is, okay, how do we address these problems? How do we make bone marrow more available to deliver and deploy on demand and easily, without needing to track down a volunteer donor? What can we do to reduce the risk of rejection so that the transplant is safer? What can we do to improve the likelihood of engraftment the first time and the speed of engraftment so the patients aren't immunocompromised for as long? All of these are things that we're working on to really make it possible to bring this lifesaving procedure to more patients."

#OssiumHealth #StemCellTherapy #RegenerativeMedicine #BoneMarrowTransplants

ossiumhealth.com

Listen to the podcast here

Kevin Caldwell, CEO, President, and Co-Founder of Ossium Health, discusses the opportunities for regenerative stem-cell therapies and the challenges of obtaining bone marrow from donors for bone marrow transplants. Ossium Health is collecting bone marrow from healthy, young donors and utilizing a cryopreservation process that enables long-term storage and on-demand availability of these cells. Ongoing clinical trials using allogeneic bone-marrow-derived cells to treat patients with acute leukemia and myelodysplastic syndrome are showing promising results.

Kevin explains, "Our mission is to improve the health, longevity, and vitality of human beings through bioengineering. We believe that regenerative therapeutics, which involve cell and gene therapies that can permanently and positively improve human biology, will be fundamental to the prevention of disease and the preservation of health as we age. One of the most powerful tools we have in achieving this goal is engineering the immune system. And in particular at Ossium, we develop therapeutics that enable us today in the clinic to treat life-threatening malignancies of the immune system, like leukemia, in patients with dire need. Into the future, the goal is to make it possible to reconstitute, reprogram, and replace a blood and immune system in a manner that can treat patients with chronic diseases and ultimately do so in a preventive manner."

"Traditionally, the major application of bone marrow in the clinic is bone marrow transplants for patients with blood cancers like leukemia. And so the patient's native immune system is ablated or annihilated and replaced with a bone marrow infusion from a healthy donor, related or unrelated. And if that bone, new bone marrow from the donor in grafts in the patient, then it replaces or it constitutes their blood and immune system."

"And so one of the things that we're working on at Ossium is, okay, how do we address these problems? How do we make bone marrow more available to deliver and deploy on demand and easily, without needing to track down a volunteer donor? What can we do to reduce the risk of rejection so that the transplant is safer? What can we do to improve the likelihood of engraftment the first time and the speed of engraftment so the patients aren't immunocompromised for as long? All of these are things that we're working on to really make it possible to bring this lifesaving procedure to more patients."

#OssiumHealth #StemCellTherapy #RegenerativeMedicine #BoneMarrowTransplants

ossiumhealth.com

Download the transcript here

Ann Bilyew, Executive VP of Health and Group General Manager at WebMD Ignite, works with hospitals, health systems, and payers to provide technology that builds trust, reduces administrative burdens on providers, and personalizes engagements with patients and members. While AI-powered solutions are showing great promise, challenges arise in deploying new technologies due to legacy infrastructure, interoperability issues, and the need to balance innovation with potential risks and costs. A strong foundation of high-quality, clinically reviewed content is key to the ability to provide accurate information on demand.

Ann explains, "We work with hospitals, health systems, payers, and essentially everybody involved in the provision or payment support in healthcare. And we work with 90% of US-based hospitals and health systems and about an equal percentage of all of the top payers in the United States."

"I'd say one of the key themes that we hear time and time again across all of our clients and all of our partners is the need to build trust and the need to stay relevant and the need to personalize engagements with consumers, with patients, with members. I mean, let's face it, humans today, we've all been trained, or humans in the United States, at least, have all been trained to have a really personalized experience with their partners and their vendors. So they expect us to know them, they expect us to understand them, they expect us to know the needs, their unique set of circumstances that make them a human. And doing that within the appropriate confines of privacy regulation and requirements is really the job at hand for many of our clients."

"And it's not just with hospitals, payers honestly have, for the most part, ancient care management platforms and ancient claims processing platforms. And look, there are good reasons for that. I mean, we like to sort of point to that as a thing, but it's not been because of negligence, or it's not been because people didn't want to improve and modernize their technology and their infrastructure. There are good reasons why what exists today exists, and part of it is resources and costs for sure. But part of it also is risk, and the risk associated with losing data or not being able to pay your clinicians if you're a health plan, or respond to your members in a timely way if you're a health plan, or not even being able to operate your ER effectively."

#WebMD #AIforHealth #MedAI #PatientEducation #PatientEngagement #DigitalHealth #DigitalHealthInnovations #PersonalizedCare #EmpoweredPatients

webmdignite.com

Listen to the podcast here

Ann Bilyew, Executive VP of Health and Group General Manager at WebMD Ignite, works with hospitals, health systems, and payers to provide technology that builds trust, reduces administrative burdens on providers, and personalizes engagements with patients and members. While AI-powered solutions are showing great promise, challenges arise in deploying new technologies due to legacy infrastructure, interoperability issues, and the need to balance innovation with potential risks and costs. A strong foundation of high-quality, clinically reviewed content is key to the ability to provide accurate information on demand.

Ann explains, "We work with hospitals, health systems, payers, and essentially everybody involved in the provision or payment support in healthcare. And we work with 90% of US-based hospitals and health systems and about an equal percentage of all of the top payers in the United States."

"I'd say one of the key themes that we hear time and time again across all of our clients and all of our partners is the need to build trust and the need to stay relevant and the need to personalize engagements with consumers, with patients, with members. I mean, let's face it, humans today, we've all been trained, or humans in the United States, at least, have all been trained to have a really personalized experience with their partners and their vendors. So they expect us to know them, they expect us to understand them, they expect us to know the needs, their unique set of circumstances that make them a human. And doing that within the appropriate confines of privacy regulation and requirements is really the job at hand for many of our clients."

"And it's not just with hospitals, payers honestly have, for the most part, ancient care management platforms and ancient claims processing platforms. And look, there are good reasons for that. I mean, we like to sort of point to that as a thing, but it's not been because of negligence, or it's not been because people didn't want to improve and modernize their technology and their infrastructure. There are good reasons why what exists today exists, and part of it is resources and costs for sure. But part of it also is risk, and the risk associated with losing data or not being able to pay your clinicians if you're a health plan, or respond to your members in a timely way if you're a health plan, or not even being able to operate your ER effectively."

#WebMD #AIforHealth #MedAI #PatientEducation #PatientEngagement #DigitalHealth #DigitalHealthInnovations #PersonalizedCare #EmpoweredPatients

webmdignite.com

Download the transcript here

Greg Farnum, Senior VP and General Manager at Audacious Inquiry, a PointClickCare company, brings expertise in health information exchange, public health, and health IT policy. Audacious is using AI to reduce administrative burdens and improve clinical workflows, facilitating data exchange, enhancing decision-making, and providing a better patient experience. Working with the Assistant Secretary for Technology Policy and other federal and state agencies, Audacious is developing tools to summarize lengthy test results, generate educational materials, and suggest relevant responses to public inquiries.

Greg explains, "We have a full-stack engineering team, a managed services team, expertise in health IT policy and regulation, health IT standards, public health, and now artificial intelligence. So we work with ASTP (Assistant Secretary for Technology Policy), which is also known as the old ONCCDC, plus a bunch of other federal and state agencies, HIEs, and public health. We are part of PointClickCare, a leading health tech company with one simple mission -- to help providers deliver exceptional care across thousands of facilities."

"ASTP has some really interesting challenges that are perfect for AI. They're dealing with some complex data analysis challenges and the creation of content for industry and the public. They also respond to thousands of public inquiries yearly. So we're helping them with all of those things and leveraging AI tools to do that."

"I'll get a little more specific. Every year, hundreds of health IT organizations and developers submit these things they call testing results associated with their real-world test plans. But there's no standard format for this. So, ASTP staff have to manually read through each of these documents. And these are big documents. They can be 50 pages, they could be 200 pages, and the staff need to go through and figure out where the answers are to these specific questions. So we've built some AI tools that can read the entire document and automatically extract the answers using things like natural language processing and other AI components."

#PointClickCare #AudaciousInquiry #AI #MedAI #ResponsibleAI #AdministrativeBurdens #DigitalHealth #Healthcare #HealthcareRegulation #ClinicianBurnout #Clinicians

ainq.com

Listen to the podcast here

Greg Farnum, Senior VP and General Manager at Audacious Inquiry, a PointClickCare company, brings expertise in health information exchange, public health, and health IT policy. Audacious is using AI to reduce administrative burdens and improve clinical workflows, facilitating data exchange, enhancing decision-making, and providing a better patient experience. Working with the Assistant Secretary for Technology Policy and other federal and state agencies, Audacious is developing tools to summarize lengthy test results, generate educational materials, and suggest relevant responses to public inquiries.

Greg explains, "We have a full-stack engineering team, a managed services team, expertise in health IT policy and regulation, health IT standards, public health, and now artificial intelligence. So we work with ASTP (Assistant Secretary for Technology Policy), which is also known as the old ONCCDC, plus a bunch of other federal and state agencies, HIEs, and public health. We are part of PointClickCare, a leading health tech company with one simple mission -- to help providers deliver exceptional care across thousands of facilities."

"ASTP has some really interesting challenges that are perfect for AI. They're dealing with some complex data analysis challenges and the creation of content for industry and the public. They also respond to thousands of public inquiries yearly. So we're helping them with all of those things and leveraging AI tools to do that."

"I'll get a little more specific. Every year, hundreds of health IT organizations and developers submit these things they call testing results associated with their real-world test plans. But there's no standard format for this. So, ASTP staff have to manually read through each of these documents. And these are big documents. They can be 50 pages, they could be 200 pages, and the staff need to go through and figure out where the answers are to these specific questions. So we've built some AI tools that can read the entire document and automatically extract the answers using things like natural language processing and other AI components."

#PointClickCare #AudaciousInquiry #AI #MedAI #ResponsibleAI #AdministrativeBurdens #DigitalHealth #Healthcare #HealthcareRegulation #ClinicianBurnout #Clinicians

ainq.com

Download the transcript here

Dr. Abe Delpassand, Founder, CEO, and Chairman of the Board at RadioMedix, is concentrated on the development of radiopharmaceuticals for cancer diagnosis and treatment. Advancements in handling radioactive materials and increased availability have enabled the growth of the use of alpha-emitting and beta-emitting radioisotopes in treating cancers that have been resistant to other therapies. Alpha-emitting radioisotopes are particularly interesting because they can cause double-strand DNA damage in cancer cells, making the probability of cancer recurrence much less likely.

Abe explains, "Just a brief introduction related to what radiopharmaceuticals are. These are drugs that have three parts, basically. One part is the radioactive material. The second part is what we call a ligand. It's like a vehicle that takes the radioactive material to the target that we have. And there is a third component, which is like a chain attaching the radioisotope to the ligand. Radiopharmaceuticals qualify as a form of therapy because we target a specific receptor antigen metabolic pathway in cancer cells, and this is how we can reach the cancer cells. It has two components: one, diagnostic and therapeutic, which is very unique to this modality because in many other cancer therapies before the treatment, we don't have any way to make sure that the patient who is receiving the treatment, that actually the drug can reach the cancer the patient has."

"We have been talking about the value of alpha-emitters in delivering high level of radiation in a targeted fashion to the cancer cells, but we in the last, I'd say 10 years or more, we have learned how to handle these isotopes. That's one aspect of the science part. The other aspect is the availability of these isotopes. Now the supply of these isotopes is becoming a lot more, and they are becoming more available."

#RadioMedix #TeamRadioMedix #Radiopharmaceuticals #TargetedAlphaTherapy #OncologyInnovation #NuclearMedicine #CancerResearch #RadiogandTherapy #PrecisionOncology #Theranostics #SPICACenter #OncologyCommunity #AlphaEmittingRadioisotopes #BetaEmittingRadioisotopes

radiomedix.com

Listen to the podcast here

Dr. Abe Delpassand, Founder, CEO, and Chairman of the Board at RadioMedix, is concentrated on the development of radiopharmaceuticals for cancer diagnosis and treatment. Advancements in handling radioactive materials and increased availability have enabled the growth of the use of alpha-emitting and beta-emitting radioisotopes in treating cancers that have been resistant to other therapies. Alpha-emitting radioisotopes are particularly interesting because they can cause double-strand DNA damage in cancer cells, making the probability of cancer recurrence much less likely.

Abe explains, "Just a brief introduction related to what radiopharmaceuticals are. These are drugs that have three parts, basically. One part is the radioactive material. The second part is what we call a ligand. It's like a vehicle that takes the radioactive material to the target that we have. And there is a third component, which is like a chain attaching the radioisotope to the ligand. Radiopharmaceuticals qualify as a form of therapy because we target a specific receptor antigen metabolic pathway in cancer cells, and this is how we can reach the cancer cells. It has two components: one, diagnostic and therapeutic, which is very unique to this modality because in many other cancer therapies before the treatment, we don't have any way to make sure that the patient who is receiving the treatment, that actually the drug can reach the cancer the patient has."

"We have been talking about the value of alpha-emitters in delivering high level of radiation in a targeted fashion to the cancer cells, but we in the last, I'd say 10 years or more, we have learned how to handle these isotopes. That's one aspect of the science part. The other aspect is the availability of these isotopes. Now the supply of these isotopes is becoming a lot more, and they are becoming more available."

#RadioMedix #TeamRadioMedix #Radiopharmaceuticals #TargetedAlphaTherapy #OncologyInnovation #NuclearMedicine #CancerResearch #RadiogandTherapy #PrecisionOncology #Theranostics #SPICACenter #OncologyCommunity #AlphaEmittingRadioisotopes #BetaEmittingRadioisotopes

radiomedix.com

Download the transcript here